Gary S. Gillheeney - Dec 5, 2024 Form 4 Insider Report for Organogenesis Holdings Inc. (ORGO)

Role
President and CEO, Director
Signature
/s/ William R. Kolb, Attorney-in-Fact
Stock symbol
ORGO
Transactions as of
Dec 5, 2024
Transactions value $
$844,851
Form type
4
Date filed
12/9/2024, 08:05 PM
Previous filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORGO Class A Common Stock Options Exercise $1.06M +1.07M +45.38% $0.99 3.42M Dec 5, 2024 Direct
transaction ORGO Class A Common Stock Sale -$67.2K -18.4K -0.54% $3.65 3.4M Dec 6, 2024 Direct F1, F2
transaction ORGO Class A Common Stock Sale -$145K -41.1K -1.21% $3.52 3.36M Dec 9, 2024 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORGO Stock Option (Right to Buy) Options Exercise $0 -1.07M -100% $0.00 0 Dec 5, 2024 Class A Common Stock 1.07M $0.99 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported above.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.6132 to $3.6858, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.48 to $3.69, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
F4 100% of the shares subject to the option are fully vested and exercisable.